ARTICLE ALAD Porphyria Is a Conformational Disease
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Hyperbilirubinemia
Porphyrins Porphyrins (Porphins) are cyclic tetrapyrol compounds formed by the linkage )). of four pyrrole rings through methenyl bridges (( HC In the reduced porphyrins (Porphyrinogens) the linkage of four pyrrole rings (tetrapyrol) through methylene bridges (( CH2 )) The characteristic property of porphyrins is the formation of complexes with the metal ion bound to nitrogen atoms of the pyrrole rings. e.g. Heme (iron porphyrin). Proteins which contain heme ((hemoproteins)) are widely distributed e.g. Hemoglobin, Myoglobin, Cytochromes, Catalase & Tryptophan pyrrolase. Natural porphyrins have substituent side chains on the eight hydrogen atoms numbered on the pyrrole rings. These side chains are: CH 1-Methyl-group (M)… (( 3 )) 2-Acetate-group (A)… (( CH2COOH )) 3-Propionate-group (P)… (( CH2CH2COOH )) 4-Vinyl-group (V)… (( CH CH2 )) Porphyrins with asymmetric arrangement of the side chains are classified as type III porphyrins while those with symmetric arrangement of the side chains are classified as type I porphyrins. Only types I & III are present in nature & type III series is more important because it includes heme. 1 Heme Biosynthesis Heme biosynthesis occurs through the following steps: 1-The starting reaction is the condensation between succinyl-CoA ((derived from citric acid cycle in the mitochondria)) & glycine, this reaction is a rate limiting reaction in the hepatic heme synthesis, it occurs in the mitochondria & is catalyzed by ALA synthase (Aminolevulinate synthase) enzyme in the presence of pyridoxal phosphate as a cofactor. The product of this reaction is α-amino-β-ketoadipate which is rapidly decarboxylated to form δ-aminolevulinate (ALA). 2-In the cytoplasm condensation reaction between two molecules of ALA is catalyzed by ALA dehydratase enzyme to form two molecules of water & one 2 molecule of porphobilinogen (PBG) which is a precursor of pyrrole. -
Targeting Proteins Self-Association in Drug Design
Targeting proteins self-association in drug design Léopold Thabault,1,2 Maxime Liberelle,1 Raphaël Frédérick1* 1 Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), B-1200 Brussels, Belgium. 2 Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain),B-1200 Brussels, Belgium. * Corresponding Author : Prof. Raphaël Frédérick Université catholique de Louvain (UCLouvain) Louvain Drug Research Institute (LDRI) Tour Van Helmont, B1.73.10 73 avenue Mounier 1200 Brussels Belgium Phone : +32 2 764 73 41 1 Abstract Protein self-association is a universal phenomenon essential for stability and molecular recognition. Disrupting constitutive homomers constitutes an original and emerging strategy in drug design. Inhibition of homomeric proteins can be achieved through direct complex disruption, subunits intercalation or by promoting inactive oligomeric states. Targeting self- interaction grants several advantages over active site inhibition thanks to the stimulation of protein degradation, the enhancement of selectivity, a sub-stoichiometric inhibition and a by- pass of compensatory mechanisms. This new landscape in protein inhibition is driven by the development of biophysical and biochemical tools suited for the study of homomeric proteins, such as DSF, native MS, FRET spectroscopy, two-dimensional NMR and X-ray crystallography. The present review covers the different aspects of this new paradigm in drug design. Keywords Protein-protein interaction; Homo-oligomers Disruptor; Protein destabilisation; Allosteric inhibition; Self-association. Teaser Disrupting protein self-association bears great therapeutic promesses and could provide exciting alternatives to active-site inhibitors. 2 1. PPI as a well-accepted paradigm in drug design The human interactome is nowadays widely considered as one of the keys to cell mechanistic regulation. -
Moonlighting Proteins in the Fuzzy Logic of Cellular Metabolism
molecules Review Moonlighting Proteins in the Fuzzy Logic of Cellular Metabolism Haipeng Liu 1 and Constance J. Jeffery 2,* 1 Center for Biomolecular Sciences, College of Pharmacy, University of Illinois at Chicago, 900 South Ashland Avenue, Chicago, IL 60607, USA; [email protected] 2 Department of Biological Sciences, University of Illinois at Chicago, 900 South Ashland Avenue, Chicago, IL 60607, USA * Correspondence: cjeff[email protected]; Tel.: +1-312-996-3168 Academic Editor: Pier Luigi Gentili Received: 30 May 2020; Accepted: 23 July 2020; Published: 29 July 2020 Abstract: The numerous interconnected biochemical pathways that make up the metabolism of a living cell comprise a fuzzy logic system because of its high level of complexity and our inability to fully understand, predict, and model the many activities, how they interact, and their regulation. Each cell contains thousands of proteins with changing levels of expression, levels of activity, and patterns of interactions. Adding more layers of complexity is the number of proteins that have multiple functions. Moonlighting proteins include a wide variety of proteins where two or more functions are performed by one polypeptide chain. In this article, we discuss examples of proteins with variable functions that contribute to the fuzziness of cellular metabolism. Keywords: moonlighting proteins; fuzzy logic; intrinsically disordered proteins; metamorphic proteins; morpheeins 1. Introduction Fuzzy logic systems include variables that can be any real number between 0 and 1 instead of being limited to the Boolean logic variables of only 0 and 1. This enables expression of complexity, uncertainty, and imprecision. In general, the vast interconnected biochemical pathways that make up the metabolism of a living cell can appear fuzzy because they are complex and hard to predict, and we have incomplete and not yet accurate knowledge. -
Structures, Functions, and Mechanisms of Filament Forming Enzymes: a Renaissance of Enzyme Filamentation
Structures, Functions, and Mechanisms of Filament Forming Enzymes: A Renaissance of Enzyme Filamentation A Review By Chad K. Park & Nancy C. Horton Department of Molecular and Cellular Biology University of Arizona Tucson, AZ 85721 N. C. Horton ([email protected], ORCID: 0000-0003-2710-8284) C. K. Park ([email protected], ORCID: 0000-0003-1089-9091) Keywords: Enzyme, Regulation, DNA binding, Nuclease, Run-On Oligomerization, self-association 1 Abstract Filament formation by non-cytoskeletal enzymes has been known for decades, yet only relatively recently has its wide-spread role in enzyme regulation and biology come to be appreciated. This comprehensive review summarizes what is known for each enzyme confirmed to form filamentous structures in vitro, and for the many that are known only to form large self-assemblies within cells. For some enzymes, studies describing both the in vitro filamentous structures and cellular self-assembly formation are also known and described. Special attention is paid to the detailed structures of each type of enzyme filament, as well as the roles the structures play in enzyme regulation and in biology. Where it is known or hypothesized, the advantages conferred by enzyme filamentation are reviewed. Finally, the similarities, differences, and comparison to the SgrAI system are also highlighted. 2 Contents INTRODUCTION…………………………………………………………..4 STRUCTURALLY CHARACTERIZED ENZYME FILAMENTS…….5 Acetyl CoA Carboxylase (ACC)……………………………………………………………………5 Phosphofructokinase (PFK)……………………………………………………………………….6 -
First Structure of Full-Length Mammalian Phenylalanine Hydroxylase Reveals the Architecture of an Autoinhibited Tetramer
First structure of full-length mammalian phenylalanine hydroxylase reveals the architecture of an autoinhibited tetramer Emilia C. Arturoa,b, Kushol Guptac, Annie Hérouxd, Linda Stitha, Penelope J. Crosse,f,g, Emily J. Parkere,f,g, Patrick J. Lollb, and Eileen K. Jaffea,1 aMolecular Therapeutics, Fox Chase Cancer Center, Temple University Health Systems, Philadelphia, PA 19111; bBiochemistry and Molecular Biology, Drexel University College of Medicine, Philadelphia, PA 19102; cBiochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104; dEnergy Sciences Directorate/Photon Science Division, Brookhaven National Laboratory, Upton, NY 11973; eBiomolecular Interaction Centre, University of Canterbury, Christchurch 8041, New Zealand; fDepartment of Chemistry, University of Canterbury, Christchurch 8041, New Zealand; and gMaurice Wilkins Centre for Molecular Biodiscovery, University of Auckland, Auckland 1142, New Zealand Edited by Judith P. Klinman, University of California, Berkeley, CA, and approved January 21, 2016 (received for review August 27, 2015) Improved understanding of the relationship among structure, dy- There are >500 disease-associated missense variants of human namics, and function for the enzyme phenylalanine hydroxylase PAH; the amino acid substitutions are distributed throughout (PAH) can lead to needed new therapies for phenylketonuria, the the 452-residue protein and among all its domains (Fig. 1A) most common inborn error of amino acid metabolism. PAH is a (7–9). Of those disease-associated variants that have been stud- multidomain homo-multimeric protein whose conformation and ied in vitro (e.g., ref. 10), some confound the allosteric response, multimerization properties respond to allosteric activation by the and some are interpreted as structurally unstable. We also sug- substrate phenylalanine (Phe); the allosteric regulation is neces- gest that the activities of some disease-associated variants may be sary to maintain Phe below neurotoxic levels. -
Allosteric Modulation of Protein Oligomerization: an Emerging Approach to Drug Design
REVIEW ARTICLE published: 24 March 2014 doi: 10.3389/fchem.2014.00009 Allosteric modulation of protein oligomerization: an emerging approach to drug design Ronen Gabizon † and Assaf Friedler* Institute of Chemistry, The Hebrew University of Jerusalem, Jerusalem, Israel Edited by: Many disease-related proteins are in equilibrium between different oligomeric forms. The Youla S. Tsantrizos, McGill regulation of this equilibrium plays a central role in maintaining the activity of these University, Canada proteins in vitro and in vivo. Modulation of the oligomerization equilibrium of proteins Reviewed by: by molecules that bind preferentially to a specific oligomeric state is emerging as a Lee Fader, Boehringer Ingelheim Pharmaceuticals, Inc., USA potential therapeutic strategy that can be applied to many biological systems such Wolfgang Jahnke, Novartis as cancer and viral infections. The target proteins for such compounds are diverse Institutes for Biomedical Research, in structure and sequence, and may require different approaches for shifting their Switzerland oligomerization equilibrium. The discovery of such oligomerization-modulating compounds *Correspondence: is thus achieved based on existing structural knowledge about the specific target proteins, Assaf Friedler, Institute of Chemistry, The Hebrew University as well as on their interactions with partner proteins or with ligands. In silico design and of Jerusalem, Safra Campus, Givat combinatorial tools such as peptide arrays and phage display are also used for discovering Ram, Jerusalem 91904, Israel compounds that modulate protein oligomerization. The current review highlights some e-mail: [email protected] of the recent developments in the design of compounds aimed at modulating the †Present address: oligomerization equilibrium of proteins, including the “shiftides” approach developed in Ronen Gabizon,California Institute our lab. -
UNIVERSITY of CALIFORNIA, IRVINE Development And
UNIVERSITY OF CALIFORNIA, IRVINE Development and application of molecular modeling methods for characterization of drug targets in Mycobacterium tuberculosis DISSERTATION submitted in partial satisfaction of the requirements for the degree of DOCTOR OF PHILOSOPHY in Pharmaceutical Sciences by Kalistyn H. Burley Dissertation Committee: Professor David L. Mobley, Chair Professor Celia W. Goulding Professor Thomas L. Poulos 2020 Chapter 2 © 2019 American Chemical Society Chapter 3 © 2019 American Chemical Society All other materials © 2020 Kalistyn H. Burley DEDICATION To my children, Aubrey and Baron – being your mother is, and will always be, my greatest accomplishment. To Scott, an amazing partner in life and in parenthood, who has never doubted me, and has also never let me settle. To my mom, dad, and brothers Kristopher and Jacob, who gave me the confidence to “jump off cliffs and build my wings on the way down.” - Ray Bradbury, 1986 And to my mentors and role models, particularly the women before me who have paved the road for my successes, I am forever indebted and committed to paying it forward. ii TABLE OF CONTENTS LIST OF FIGURES iv LIST OF TABLES vi ACKNOWLEDGMENTS vii VITA ix ABSTRACT OF THE DISSERTATION xii CHAPTER 1: An introduction to tuberculosis and 1 computational methods for structure-based drug design References 16 CHAPTER 2: Enhancing side chain sampling using 19 non-equilibrium candidate Monte Carlo References 59 CHAPTER 3: Structure of a Mycobacterium tuberculosis heme- 63 degrading protein, MhuD, variant in complex -
A High Urinary Urobilinogen / Serum Total Bilirubin Ratio Reported in Abdominal Pain Patients Can Indicate Acute Hepatic Porphyria
A High Urinary Urobilinogen / Serum Total Bilirubin Ratio Reported in Abdominal Pain Patients Can Indicate Acute Hepatic Porphyria Chengyuan Song Shandong University Qilu Hospital Shaowei Sang Shandong University Qilu Hospital Yuan Liu ( [email protected] ) Shandong University Qilu Hospital https://orcid.org/0000-0003-4991-552X Research Keywords: acute hepatic porphyria, urinary urobilinogen, serum total bilirubin Posted Date: June 14th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-587707/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/10 Abstract Background: Due to its variable symptoms and nonspecic laboratory test results during routine examinations, acute hepatic porphyria (AHP) has always been a diagnostic dilemma for physicians. Misdiagnoses, missed diagnoses, and inappropriate treatments are very common. Correct diagnosis mainly depends on the detection of a high urinary porphobilinogen (PBG) level, which is not a routine test performed in the clinic and highly relies on the physician’s awareness of AHP. Therefore, identifying a more convenient indicator for use during routine examinations is required to improve the diagnosis of AHP. Results: In the present study, we retrospectively analyzed laboratory examinations in 12 AHP patients and 100 patients with abdominal pain of other causes as the control groups between 2015 and 2021. Compared with the control groups, AHP patients showed a signicantly higher urinary urobilinogen level during the urinalysis (P < 0.05). However, we showed that the higher urobilinogen level was caused by a false- positive result due to a higher level of urine PBG in the AHP patients. Hence, we used serum total bilirubin, an upstream substance of urinary urobilinogen synthesis, for calibration. -
Carbon Monoxide Production Associated with Ineffective Erythropoiesis * PETER Whitef RONALD F
The Journal of Clinical Investigation Vol. 46, No. 12, 1967 Carbon Monoxide Production Associated with Ineffective Erythropoiesis * PETER WHITEf RONALD F. COBURN,§ WILLIAM J. W1LLIAMS,II MANFRED I. GOLDWEIN, MARY L. ROTHER, AND BRENDA C. SHAFER (From the Department of Medicine, School of Medicine and the Department of Physiology, Graduate Division, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania) Abstract. The rate of endogenous carbon monoxide production (Vco), de- termined by the closed rebreathing system technique, was elevated above the normal range in four of five patients studied with ineffective erythropoiesis (four patients with primary refractory anemia, one with thalassemia). The mean molar ratio of Vco to Vheme (rate of circulating heme catabolism, de- termined from 51Cr red cell survival curves) was 3.0 ± 0.6 (SE), indicating that most of the CO originated from sources other than circulating erythrocyte hemoglobin, in contrast to previous findings in patients with hemolytic ane- mia, where Vco paralleled Vheme closely. After administration of glycine-2-4C to these patients, endogenous CO was isolated by washout of body CO stores at high PO2 or by reacting peripheral venous blood samples with ferricyanide. The CO was then oxidized to CO2 by palladium chloride and trapped for counting in a liquid scintillation spec- trometer. "Early labeled" peaks of 14CO were demonstrated which paralleled "early labeled" peaks of stercobilin and preceded maximal labeling of circu- lating heme. Production of "early labeled" 14CO in patients with ineffective erythropoiesis was greatly increased, up to 14 times that found in a normal subject. The increased Vco and "early 14CO" production shown by these patients are presumably related mainly to heme catabolism in the marrow. -
PKM2, a Central Point of Regulation in Cancer Metabolism
Hindawi Publishing Corporation International Journal of Cell Biology Volume 2013, Article ID 242513, 11 pages http://dx.doi.org/10.1155/2013/242513 Review Article PKM2, a Central Point of Regulation in Cancer Metabolism Nicholas Wong,1,2,3,4 Jason De Melo,1,2,3,4 and Damu Tang1,2,3,4 1 Division of Nephrology, Department of Medicine, McMaster University, Hamilton, ON, Canada L8S 4L8 2 Division of Urology, Department of Surgery, McMaster University, Hamilton, ON, Canada L8S 4L8 3 Father Sean O’Sullivan Research Centre, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada L8N 4A6 4 The Hamilton Center for Kidney Research, St. Joseph’s Healthcare Hamilton, Hamilton, ON, Canada L8N 4A6 Correspondence should be addressed to Damu Tang; [email protected] Received 2 December 2012; Revised 11 January 2013; Accepted 13 January 2013 Academic Editor: Claudia Cerella Copyright © 2013 Nicholas Wong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Aerobic glycolysis is the dominant metabolic pathway utilized by cancer cells, owing to its ability to divert glucose metabolites from ATP production towards the synthesis of cellular building blocks (nucleotides, amino acids, and lipids) to meet the demands of proliferation. The M2 isoform of pyruvate kinase (PKM2) catalyzes the final and also a rate-limiting reaction in the glycolytic pathway. In the PK family, PKM2 is subjected to a complex regulation by both oncogenes and tumour suppressors, which allows for a fine-tone regulation of PKM2 activity. -
Biochemical Differentiation of the Porphyrias
Clinical Biochemistry, Vol. 32, No. 8, 609–619, 1999 Copyright © 1999 The Canadian Society of Clinical Chemists Printed in the USA. All rights reserved 0009-9120/99/$–see front matter PII S0009-9120(99)00067-3 Biochemical Differentiation of the Porphyrias J. THOMAS HINDMARSH,1,2 LINDA OLIVERAS,1 and DONALD C. GREENWAY1,2 1Division of Biochemistry, The Ottawa Hospital, and the 2Department of Pathology and Laboratory Medicine, University of Ottawa, 501 Smyth Road, Ottawa, Ontario K1H 8L6, Canada Objectives: To differentiate the porphyrias by clinical and biochem- vals for urine, fecal, and blood porphyrins and their ical methods. precursors in the various porphyrias and in normal Design and methods: We describe levels of blood, urine, and fecal porphyrins and their precursors in the porphyrias and present an subjects and have devised an algorithm for investi- algorithm for their biochemical differentiation. Diagnoses were es- gation of these diseases. Except for Porphyria Cuta- tablished using clinical and biochemical data. Porphyrin analyses nea Tarda (PCT), our numbers of patients in each were performed by high performance liquid chromatography. category of porphyria are small and therefore our Results and conclusions: Plasma and urine porphyrin patterns reference ranges for these should be considered were useful for diagnosis of porphyria cutanea tarda, but not the acute porphyrias. Erythropoietic protoporphyria was confirmed by approximate. erythrocyte protoporphyrin assay and erythrocyte fluorescence. Acute intermittent porphyria was diagnosed by increases in urine Materials and methods delta-aminolevulinic acid and porphobilinogen and confirmed by reduced erythrocyte porphobilinogen deaminase activity and nor- REAGENTS AND CHEMICALS mal or near-normal stool porphyrins. -
Porphyrins and Bile Pigments: Metabolism and Disorders Dr
Porphyrins and bile pigments: metabolism and disorders Dr. Jaya Chaturvedi Porphyrins • Porphyrins are cyclic compounds formed by the linkage of four pyrrole rings through methyne (ÓHC—) bridges.In the naturally occurring porphyrins, various side chains replace the eight numbered hydrogen atoms of the pyrroles. • Porphyrins have had different structures depend on side chains that are attached to each of the four pyrrole rings. For example; Uroporphyrin, coporporphyyrin and protoporphyrin IX (heme). • The most prevalent metalloporphyrin in humans is heme, which consists of one ferrous (Fe2+) iron ion coordinated at the center of the tetrapyrrole ring of protoporphyrin IX. What is bilirubin? •Bilirubin is a yellowish pigment found in bile, a fluid made by the liver. •The breakdown product of Hgb from injured RBCs and other heme containing proteins. •Produced by reticuloendothelial system •Released to plasma bound to albumin •Hepatocytes conjugate it and excrete through bile channels into small intestine. Bilirubin di-glucoronid Structure of heme: • Heme structure: a porphyrin ring coordinated with an atom of iron side chains: methyl, vinyl, propionyl • Heme is complexed with proteins to form: • Hemoglobin, myoglobin and cytochromes Pathway of Heme Biosynthesis. Heme biosynthesis begins in the mitochondria from glycine and succinyl- CoA, continues in the cytosol, and ultimately is completed within the mitochondria. The heme that it produced by this biosynthetic pathway is identified as heme b. PBG: porphobilinogen; ALA: δ- aminolevulinic